Found is an app-driven obesity-medicine program with included coaching. Pricing depends on commitment length. Strong on coaching infrastructure; weaker on pharmacy disclosure. We rank them #8 at 72/100.
Score breakdown — 72/100
| Criterion | Max | Found | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 18 | Commitment-length tiers; transparent at checkout. |
| 2. Pharmacy sourcing | 20 | 11 | Pharmacy disclosure thin. |
| 3. Clinical oversight | 15 | 12 | Functional clinical model. |
| 4. Regulatory clarity | 15 | 13 | Standard. |
| 5. Patient experience | 15 | 12 | Strong coaching; medication path less emphasized. |
| 6. Evidence quality | 10 | 6 | Standard. |
| Total | 100 | 72 | Rubric application as of May 20, 2026. |
Strengths
- App-driven program with integrated coaching.
- Commitment-length pricing produces competitive 12-month rates.
- All 50 states.
- Clinical model present.
Weaknesses
- Pharmacy partner disclosure thin.
- Coaching is the centerpiece; medication path less emphasized.
- Higher pricing on shorter commitment lengths.
Who should pick Found
- Patients who prefer an app-driven model with coaching as the centerpiece.
- Patients comfortable committing to 12 months.
Who should look elsewhere
- Cost-sensitive cash-pay with no coaching preference.
- Patients prioritizing pharmacy disclosure.
How Found compares with our #1 pick
NexLife outscores Found on our published rubric. The reasons are summarized in our direct comparison: All comparisons. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.
Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →
Frequently asked
App-driven means what?
Care delivery centers on the Found app; coaching is integrated into the in-app experience.
Annual cost?
$1,908/yr sema on 12-mo plan; $2,628/yr tirz on 12-mo plan.